Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives $52.33 Average Price Target from Analysts

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has been assigned a consensus recommendation of “Moderate Buy” from the eight research firms that are presently covering the firm, Marketbeat.com reports. Four analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $52.33.

AGIO has been the subject of a number of research analyst reports. StockNews.com raised Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, November 9th. Raymond James reaffirmed an “outperform” rating and issued a $51.00 target price on shares of Agios Pharmaceuticals in a report on Thursday, October 10th. Leerink Partners cut shares of Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and decreased their price target for the stock from $60.00 to $56.00 in a research note on Friday, September 27th. Scotiabank lifted their price objective on shares of Agios Pharmaceuticals from $51.00 to $53.00 and gave the company a “sector outperform” rating in a research note on Friday, November 1st. Finally, Leerink Partnrs lowered Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, September 27th.

Insider Buying and Selling at Agios Pharmaceuticals

In related news, CFO Cecilia Jones sold 2,542 shares of the firm’s stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $49.03, for a total value of $124,634.26. Following the completion of the sale, the chief financial officer now owns 20,158 shares in the company, valued at $988,346.74. This trade represents a 11.20 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 4.93% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Agios Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. ProShare Advisors LLC raised its stake in shares of Agios Pharmaceuticals by 9.0% during the 1st quarter. ProShare Advisors LLC now owns 13,917 shares of the biopharmaceutical company’s stock worth $407,000 after buying an additional 1,152 shares during the last quarter. Entropy Technologies LP purchased a new stake in shares of Agios Pharmaceuticals in the first quarter valued at about $286,000. State Board of Administration of Florida Retirement System grew its position in shares of Agios Pharmaceuticals by 13.7% in the first quarter. State Board of Administration of Florida Retirement System now owns 18,017 shares of the biopharmaceutical company’s stock valued at $527,000 after purchasing an additional 2,170 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Agios Pharmaceuticals by 0.8% during the 1st quarter. Vanguard Group Inc. now owns 5,572,021 shares of the biopharmaceutical company’s stock worth $162,926,000 after purchasing an additional 44,583 shares in the last quarter. Finally, CANADA LIFE ASSURANCE Co raised its position in shares of Agios Pharmaceuticals by 1.8% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 31,144 shares of the biopharmaceutical company’s stock worth $911,000 after purchasing an additional 540 shares during the last quarter.

Agios Pharmaceuticals Price Performance

Shares of NASDAQ:AGIO opened at $54.62 on Friday. Agios Pharmaceuticals has a 12 month low of $20.96 and a 12 month high of $62.58. The firm has a market capitalization of $3.11 billion, a P/E ratio of 4.81 and a beta of 0.75. The company’s fifty day moving average price is $47.03 and its 200 day moving average price is $44.28.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.